Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Differences in Histone Acetylation Levels in CD34+ Cells between Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Correlation between Higher Levels of Histone 2B Acetylation and Survival in AML.

M. Gorre, I. Jilani, R. Chang, J. Bareng, H. Chan, M. Keating, H. Kantarjian, E. Estey, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 2769.

https://doi.org/10.1182/blood.V106.11.2769.2769

Published: 2005

Journal Articles

4E-Binding Protein 1 (4E-BP1) in CD34+ Cells as Measured by Quantitative Flow Cytometry Is an Independent Prognostic Factor in Patients with Acute Myeloid Leukemia.

M. Gorre, I. Jilani, R. Chang, J. Bareng, H. Chan, M. Keating, H. Kantarjian, E. Estey, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 2772.

https://doi.org/10.1182/blood.V106.11.2772.2772

Published: 2005

Journal Articles

Plasma Is a Reliable Source of mRNA for Testing IgVH Mutation Status in Patients with Chronic Lymphocytic Leukemia.

W. Ma, I. Jilani, M. Gorre, M. Keating, H. Chan, R. Tseng, H. Kantarjian, S. O’Brien, F. J. Giles, M. Albitar

Blood (2005) 106 (11): 2949.

https://doi.org/10.1182/blood.V106.11.2949.2949

Published: 2005

Journal Articles

Novel Quantitative Flow Cytometry-Based Signaling Assays Reveal a Potential Role for HSP90 Inhibitors in the Treatment of JAK2 Mutant-Positive Diseases.

M. Gorre, I. Jilani, H. Kantarjian, F. Giles, A. Hannah, M. Albitar

Blood (2005) 106 (11): 3526.

https://doi.org/10.1182/blood.V106.11.3526.3526

Published: 2005

Journal Articles

Measurement of HSP90 and HSP70 in CD34-Positive Cells: Lower Levels in Myelodysplastic Syndrome Than in Acute Myeloid Leukemia and Correlation with Clinical Behavior.

M. Gorre, I. Jilani, R. Chang, H. Chan, R. Urcia, M. Keating, H. Kantarjian, E. Estey, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 3426.

https://doi.org/10.1182/blood.V106.11.3426.3426

Published: 2005

Journal Articles

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph + ALL).

Hagop M. Kantarjian, MD, O. Ottman, MD, Jorge Cortes, MD, M. Wassman, MD, L. Wunderle, MD, K. Bhalla, MD, D. Jones, MD, A. Hochhaus, MD, P. Rae, L. Alland, MD, M. Dugan, MD, M. Albitar, MD, Francis Giles, MD

Blood (2005) 106 (11): 37.

https://doi.org/10.1182/blood.V106.11.37.37

Published: 2005

Journal Articles

Phase 1 Clinical Trial of KOS-953 + Bortezomib (BZ) in Relapsed Refractory Multiple Myeloma (MM).

Asher Alban Chanan-Khan, MD, P. G. Richardson, MD, M. Alsina, MD, M. Carroll, MD, S. Lonial, MD, A. Krishnan, MD, M. Albitar, MD, Y. Zhou, MD, C. Mitsiades, MD, G. Cropp, MS, A. L. Hannah, MD, K. C. Anderson, MD

Blood (2005) 106 (11): 362.

https://doi.org/10.1182/blood.V106.11.362.362

Published: 2005

Journal Articles

Hypomethylation Therapy of Decitabine in Patients with Myelodysplastic Syndromes (MDS) Induces Apoptosis and Reduces Proliferation.

I. Jilani, H. Kantarjian, M. Gorre, J.-P. Issa, J. Bennett, A. Raza, F. Ravandi, H. Saba, M. Albitar

Blood (2005) 106 (11): 371.

https://doi.org/10.1182/blood.V106.11.371.371

Published: 2005

Journal Articles

Hemizygous/Homozygous and Heterozygous JAK2 Mutation Detected in Plasma of Patients with Myeloproliferative Diseases: Correlation with Clinical Behavior.

W. Ma, H. Kantarjian, I. Jilani, M. Gorre, F. Giles, J. Cortes, S. Verstovsek, S. O’Brien, M. Keating, M. Albitar

Blood (2005) 106 (11): 2593.

https://doi.org/10.1182/blood.V106.11.2593.2593

Published: 2005

Journal Articles

Discrepancy in Detecting Bcr-Abl Kinase Domain Mutations between Cells from Bone Marrow and Cells from Peripheral Blood, and Greater Concordance between Bone Marrow Cells and Plasma Free RNA.

W. Ma, H. Kantarjian, I. Jilani, M. Gorre, Ottmann, K. Bhalla, F. Giles, M. Albitar

Blood (2005) 106 (11): 4849.

https://doi.org/10.1182/blood.V106.11.4849.4849

Published: 2005

Journal Articles

Coexistence of Mutated and Unmutated IgVH Forms in Patients with Chronic Lymphocytic Leukemia.

M. Sheikholeslami, W. Ma, J. Uyeji, K. Tornyos, L. Cone, S. Mamus, M. Keating, M. Albitar

Blood (2005) 106 (11): 4984.

https://doi.org/10.1182/blood.V106.11.4984.4984

Published: 2005

Journal Articles

Soluble Syndecan-1 (sCD138) Is an Independent Prognostic Factor in Patients with Chronic Lymphocytic Leukemia.

I. Jilani, M. Keating, W. William, A. Ferrajoli, H. Kantarjian, S. M. O’Brien, F. J. Giles, M. Albitar

Blood (2005) 106 (11): 713.

https://doi.org/10.1182/blood.V106.11.713.713

Published: 2005

Journal Articles

Measurement of Free Circulating Bcr-Abl Fusion Protein and Its Phosphorylation in Patients with Chronic Myeloid Leukemia.

I. Jilani, H. Kantarjian, H. Faraji, M. Gorre, J. Cortes, O. Ottmann, K. Bhalla, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 2006.

https://doi.org/10.1182/blood.V106.11.2006.2006

Published: 2005

Journal Articles

Plasma RNA Is More Reliable Than Peripheral Blood Cells for Monitoring Molecular Response to Imatinib in Patients with Chronic Myeloid Leukemia.

W. Ma, R. Tseng, M. Gorre, I. Jilani, M. Keating, H. Kantarjian, J. Cortes, S. O’Brien, F. Giles, M. Albitar

Blood (2005) 106 (11): 2007.

https://doi.org/10.1182/blood.V106.11.2007.2007

Published: 2005

Journal Articles

Phosphorylation Levels of BCR-ABL, Stat5, and CrkL Proteins in Imatinib-Resistant CML Patients as Compared to Previously Untreated CML Patients: Implication of Poor Drug Binding and Activation of Alternate Pathways.

M. Gorre, H. Kantarjian, I. Jilani, J. Cortes, A. Salvado, P. Rae, L. Alland, M. Dugan, O. Ottmann, K. Bhalla, F. Giles, M. Albitar

Blood (2005) 106 (11): 2001.

https://doi.org/10.1182/blood.V106.11.2001.2001

Published: 2005

Journal Articles

A Phase I/II Study of AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, on a Continuous Daily Dosing Schedule in Adult Patients (pts) with Imatinib-Resistant Advanced Phase Chronic Myeloid Leukemia (CML) or Relapsed/Refractory Philadelphia Chromosome (Ph+) Acute Llymphocytic Leukemia (ALL).

Francis Giles, MD, H. Kantarjian, MD, B. Wassmann, J. Cortes, MD, S. O’Brien, MD, C. Tanaka, P. Rae, W. Mietlowski, A. Romano, L. Alland, M. Dugan, M. Albitar, MD, O. Ottmann

Blood (2004) 104 (11): 22.

https://doi.org/10.1182/blood.V104.11.22.22

Published: 2004

Journal Articles

p16INK4A and p15INK4B gene deletions in primary leukemias

MA Haidar, XB Cao, T Manshouri, LL Chan, A Glassman, HM Kantarjian, MJ Keating, MS Beran, M Albitar

Blood (1995) 86 (1): 311–315.

https://doi.org/10.1182/blood.V86.1.311.bloodjournal861311

Published: 1995

Journal Articles

Transgenic mice carrying the erythropoietin gene promoter linked to lacZ express the reporter in proximal convoluted tubule cells after hypoxia

F Loya, Y Yang, H Lin, E Goldwasser, M Albitar

Blood (1994) 84 (6): 1831–1836.

https://doi.org/10.1182/blood.V84.6.1831.1831

Published: 1994

Journal Articles

The human MDM-2 oncogene is overexpressed in leukemias

CE Bueso-Ramos, Y Yang, E deLeon, P McCown, SA Stass, M Albitar

Blood (1993) 82 (9): 2617–2623.

https://doi.org/10.1182/blood.V82.9.2617.2617

Published: 1993

Journal Articles

Developmental switching of messenger RNA expression from the human alpha-globin cluster: fetal/adult pattern of theta-globin gene expression

M Albitar, A Care, C Peschle, SA Liebhaber

Blood (1992) 80 (6): 1586–1591.

https://doi.org/10.1182/blood.V80.6.1586.1586

Published: 1992

NARROW

Differences in Histone Acetylation Levels in CD34+ Cells between Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Correlation between Higher Levels of Histone 2B Acetylation and Survival in AML.

4E-Binding Protein 1 (4E-BP1) in CD34+ Cells as Measured by Quantitative Flow Cytometry Is an Independent Prognostic Factor in Patients with Acute Myeloid Leukemia.

Plasma Is a Reliable Source of mRNA for Testing IgVH Mutation Status in Patients with Chronic Lymphocytic Leukemia.

Novel Quantitative Flow Cytometry-Based Signaling Assays Reveal a Potential Role for HSP90 Inhibitors in the Treatment of JAK2 Mutant-Positive Diseases.

Measurement of HSP90 and HSP70 in CD34-Positive Cells: Lower Levels in Myelodysplastic Syndrome Than in Acute Myeloid Leukemia and Correlation with Clinical Behavior.

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph + ALL).

Phase 1 Clinical Trial of KOS-953 + Bortezomib (BZ) in Relapsed Refractory Multiple Myeloma (MM).

Hypomethylation Therapy of Decitabine in Patients with Myelodysplastic Syndromes (MDS) Induces Apoptosis and Reduces Proliferation.

Hemizygous/Homozygous and Heterozygous JAK2 Mutation Detected in Plasma of Patients with Myeloproliferative Diseases: Correlation with Clinical Behavior.

Discrepancy in Detecting Bcr-Abl Kinase Domain Mutations between Cells from Bone Marrow and Cells from Peripheral Blood, and Greater Concordance between Bone Marrow Cells and Plasma Free RNA.

Coexistence of Mutated and Unmutated IgVH Forms in Patients with Chronic Lymphocytic Leukemia.

Soluble Syndecan-1 (sCD138) Is an Independent Prognostic Factor in Patients with Chronic Lymphocytic Leukemia.

Measurement of Free Circulating Bcr-Abl Fusion Protein and Its Phosphorylation in Patients with Chronic Myeloid Leukemia.

Plasma RNA Is More Reliable Than Peripheral Blood Cells for Monitoring Molecular Response to Imatinib in Patients with Chronic Myeloid Leukemia.

Phosphorylation Levels of BCR-ABL, Stat5, and CrkL Proteins in Imatinib-Resistant CML Patients as Compared to Previously Untreated CML Patients: Implication of Poor Drug Binding and Activation of Alternate Pathways.

A Phase I/II Study of AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, on a Continuous Daily Dosing Schedule in Adult Patients (pts) with Imatinib-Resistant Advanced Phase Chronic Myeloid Leukemia (CML) or Relapsed/Refractory Philadelphia Chromosome (Ph+) Acute Llymphocytic Leukemia (ALL).

p16INK4A and p15INK4B gene deletions in primary leukemias

Transgenic mice carrying the erythropoietin gene promoter linked to lacZ express the reporter in proximal convoluted tubule cells after hypoxia

The human MDM-2 oncogene is overexpressed in leukemias

Developmental switching of messenger RNA expression from the human alpha-globin cluster: fetal/adult pattern of theta-globin gene expression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only